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1. Introduction
Hutchinson-Gilford Progeria Syndrome (HGPS) is a lethal congenital disorder, characterised
by premature appearance of accelerated ageing in children. Although HGPS was first descri‐
bed by Jonathan Hutchinson [1] and then by Hastings Gilford [2] more than a century ago, it
was not until 2003 that the genetic basis of HGPS was uncovered [3, 4]. Approximately 90%
of HGPS patients have an identical mutation in paternal allele of the LMNA gene – a substi‐
tution of cytosine to thymine at nucleotide 1824, c.1824C>T. Although apparently a silent
mutation (that is, no change in the amino acid, G608G), it causes aberrant mRNA splicing,
which leads to the production of a truncated and partially processed pre-lamin A protein
called “progerin” [3, 4]. Accumulation of progerin is thought to underlie the pathophysiolo‐
gy of HGPS. Individuals with HGPS appear to show ageing-related phenotypes at a much
faster rate than normal, consequently leaving young children with the appearance and
health conditions of an aged individual. The reported incidence of HGPS is 1 in 4 to 8 mil‐
lion newborns and 89 patients are currently known to be alive with HGPS worldwide [5].
The observed male to female ratio of incidence of HGPS is 1.2:1 and there has been no report
on ethnic-specific recurrence. HGPS affect diverse body systems including growth, skeleton,
body fat, skin, hair, and cardiovascular system. However, patients show no defects in their
mental and intellectual abilities [6-8]. Surprisingly, progerin has also been found in normal
unaffected individuals and its level increases with age, suggesting a similar genetic mecha‐
nism in progeria as in normal physiological ageing. Thus, numerous animal models have
been developed to better understand the mechanism(s) of HGPS and to develop cure for this
devastating disease.
In this chapter, the main aspects of HGPS such as signs and symptoms, genetic basis, animal
models, and treatments will be discussed.
© 2013 Baek et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Signs and symptoms
The median age at diagnosis of HGPS is 2.9 years [6]. The diagnosis is generally straightfor‐
ward as affected patients show classical symptoms and strongly resembles one another. The
affected individuals display no signs of disease at birth, but within their first years of life
they gradually develop an appearance often referred to as aged-like [9, 10]. Some of the typi‐
cal physical characteristics of HGPS include alopecia (loss of hair including scalp and eye‐
brows), prominent scalp veins and forehead, classical facial features including frontal
bossing, protruding ears with absent lobes, a glyphic (broad, mildly concave nasal ridge)
nose, prominent eyes, thin lips and micrognathia (small jaw) with a vertical midline groove
in the chin [7, 11, 12] (Figure 1). Abnormal and delayed dentition is also common, and thin
and often tight skin results from significant loss of subcutaneous fat [7, 10] (Figure 1). HGPS
patients have high-pitched voices, a horse-riding stance, limited joint mobility and have
short stature (median final height of 100-110 cm; median final weight of 10-15 kg). As they
mature, they develop osteolysis, particularly involving the distal phalanges and clavicles
[6-8, 11, 13]. On average, death occurs at the age of 13, with at least 90% of HGPS subjects
dying from progressive atherosclerosis of the coronary and cerebrovascular arteries [7].
Figure 1. Photographs of a 7 year-old girl with HGPS (LMNA c.1824C>T, p.G608G). This patient has typical pheno‐
types, including alopecia, thin and tight skin, loss of subcutaneous fat, prominent scalp veins and forehead, prominent
eyes, protruding ears, thin lips, and small jaw. Photos were from courtesy of The Progeria Research Foundation.
Recently, Olive et al. reported similarities between many aspects of cardiovascular disease in
HGPS patients and normal adult individuals with atherosclerosis and suggested that pro‐
gerin may be a contributor to the risk of atherosclerosis in the general population [14].
HGPS patients exhibited features that are classically associated with the atherosclerosis of
ageing, including presence of plaques in the coronary arteries, arterial lesions showing calci‐
fication, inflammation, and evidence of plaque erosion or rupture. Authors speculated that
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progerin accumulation in vascular cells causes nuclear defects and increases susceptibility to
mechanical strain that in turn triggers cell death and inflammatory response, giving rise to
atherosclerosis [14].
Interestingly, despite the presence of multiple premature ageing symptoms, many other or‐
gans, such as liver, kidney, lung, brain, gastrointestinal tract, and bone marrow, appear to
be unaffected. Furthermore, not all of the ageing processes are advanced in affected chil‐
dren. For example, the prevalence of mental deterioration, cancer, and cataract, is not higher
in HGPS patients [7]. To date, there are scarce explanations as to why only certain organs
are affected in HGPS. Nevertheless, researchers have been trying to clarify some of these
puzzling observations. Recently, Jung and colleagues suggested that the absence of cogni‐
tive deficits in HGPS patients may be explained by the down regulation of pre-lamin A ex‐
pression in the brain [15]. Furthermore, authors hypothesised that low level of pre-lamin A
in the brain may be regulated by a brain-specific microRNA (miRNA), miRNA-9. In support
of the result from this study, Nissan et al. lately published a promising result showing that
miRNA-9 inversely regulates lamin A and progerin expression in neural cells and proposed
that protection of neural cells from toxic accumulation of progerin in HGPS may be due to
expression of miRNA-9 [16]. Further studies, possibly using animal models, are required to
investigate changes in the expression of miRNA-9 and its effects on the level of progerin in
the brain.
The clinical features seen in HGPS strongly resemble several aspects of natural ageing. For
this reason, HGPS has served as a useful model for deciphering some of the mechanisms un‐
derlying physiological ageing. The first evidence for changes of nuclear architecture during
the normal ageing process came from work in C. elegans [17]. In this study, the authors dem‐
onstrated that nuclear defects accumulate during ageing and suggested that HGPS may be a
result of increased rate of the normal ageing process [17]. Scaffidi and Misteli showed that
cells from HGPS patients and normally aged individuals share several common nuclear de‐
fects [18]. In addition, a small amount of progerin protein was detected in protein extracts
derived from elderly individuals which was absent in young samples [19]. Rodriguez et al.
quantified the levels of progerin transcripts using real time quantitative RT-PCR and
showed that the progerin transcript is present in unaffected old individuals, though at a
very low level compared to HGPS patients, and this level increased with in vitro ageing, sim‐
ilarly to HGPS cells [20]. Recently, Olive and others have also reported that although the lev‐
el of progerin is much higher in HGPS patients, progerin is also present in the coronary
arteries of non-HGPS ageing individuals and significantly increases with advancing age
[14]. On the whole, accumulation of progerin, which is formed sparsely over time as a result
of the ageing process, appears to be a possible candidate and partially responsible for cellu‐
lar senescence and genomic instability that is observed in ageing cells. In HGPS, this occurs
at a substantially faster rate compared to normally-aged cells due to enhanced use of the
cryptic splice donor site, producing higher level of progerin. The relationship between this
disease of accelerating ageing and the onset of analogous symptoms during the lifespan of a
normal individual is unclear. Nevertheless, the idea that progerin may play a role in general
human ageing is supported by the numerous studies mentioned above.
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3. Genetic basis
The LMNA gene is known to be a hotspot for disease-causing mutations and has gained
much attention due to its association with a variety of human diseases. To date, more than
400 mutations spreading across the protein-coding region of the LMNA gene have been dis‐
covered (see review [21]). The LMNA gene is found at chromosome 1q21.2-q21.3 and is com‐
posed of 12 exons. Through alternative splicing, the LMNA gene encodes the A-type lamins,
lamins A and C (lamin A, AΔ10, C, and C2), of which lamin A (encoded by exons 1-12) and
lamin C (encoded by exons 1-10) are the major isoforms expressed in all differentiated cells
in vertebrates [22, 23]. The B-type lamins, lamins B1 and B2, are another type of lamins,
which are encoded by the LMNB1 and LMNB2 genes, respectively. The B-type lamins are
found in all cells and are expressed during development. Lamin A, C, B1 and B2 are key
structural components of the nuclear lamina, an intermediate filament structure that lies on
the inner surface of the inner nuclear membrane and is responsible for maintaining structur‐
al stability and organising chromatin (see review [24]). The nuclear lamina determines the
shape and size of the cell nucleus, and is involved in DNA replication and transcription. In
addition, nuclear lamina has been shown to interact with several nuclear membrane-associ‐
ated proteins, transcription factors, as well as heterochromatin itself. The nuclear lamina is
required for most nuclear activities, such as chromatin organisation, DNA replication, cell
cycle regulation, nuclear positioning within the cell, assembly/disassembly of the nucleus
during cell division, as well as for modulating master regulatory genes and signalling path‐
ways [25-27]. There are more than 10 different disorders that are caused by mutations in the
LMNA gene and these disorders are collectively called laminopathies and include neuropa‐
thies, muscular dystrophies, cardiomyopathies, lipodystrophies, in addition to progeroid
syndromes (see Chapter on Laminopathies).
The genetic basis for HGPS was unknown until it was found to be a single nucleotide muta‐
tion on the paternal allele with autosomal-dominant expression [3, 4]. Although numerous
mutations have been reported to cause HGPS [4, 28-33], approximately 90% of cases are
caused by a recurrent, dominant, de novo heterozygous silent amino acid substitution at c.
1824C>T, G608G (a change from glycine GGC to glycine GGT, referred to as G608G) of the
LMNA gene [4] (Figure 2). This mutation is located in exon 11 of LMNA gene and results in
increased activation of the cryptic splice donor site, splicing the LMNA gene at 5 nucleotides
upstream of the mutation, leading to accumulation of aberrant mRNA transcript, missing
150 nucleotides from normal pre-lamin A. This mutated mRNA is then translated into a pro‐
tein termed ‘progerin’, which is missing 50 amino-acid residues from its C-terminal region.
It has been suggested that different mutations cause activation of the same cryptic splice site
in exon 11 of LMNA gene, and disease severity is correlated with the usage of this splice site
(Figure 2). For instance, Moulson and others described two patients with particularly severe
progeroid symptoms, clearly more severe than a typical case of HGPS [30]. In both cases, the
amount of progerin relative to properly processed pre-lamin A was significantly greater
than that of in typical HGPS, suggesting that the severity of the disease appears to be de‐
pendent on the amount of progerin in cells [30]. Very recently, another more severe case was
reported by Reunert et al [31]. This patient had the heterozygous LMNA mutation c.
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1821G>A, which lead to neonatal progeria with death in the first year of life [31]. Authors
showed that the ratio of progerin protein to mature lamin A was higher in this patient com‐
pared to classical HGPS and also proposed that this ratio determines the disease severity in
progeria [31]. Opposite cases were also shown by Hisama and colleagues. In this study, mu‐
tations at the junction of exon 11 and intron 11 of the LMNA gene resulted in a considerably
lower level of progerin compared to HGPS, giving rise to an adult-onset progeroid syn‐
drome closely resembling Werner syndrome [33].
Figure 2. A schematic diagram showing point mutations leading to increased activation of a cryptic splice site within
exon 11 of the LMNA gene [4, 30, 31, 33]. All of these mutations results in an internal deletion of 150 nucleotides of
exon 11, ultimately leading to the production of an abnormally processed protein called ‘progerin’. It is interesting to
note that the normal LMNA sequence can also be spliced abnormally, removing 150 nucleotides of exon 11, in healthy
individuals and this incidence may increase with age, leading to cellular senescence [18, 20].
Under the normal condition, mature lamin A protein is produced from a precursor, pre-lam‐
in A, via a series of post-translational processing steps, which begins at the C-terminal
end. The CaaX  motif at the C-terminal tail (where the C  is a cysteine, the a  residues are
aliphatic amino acids, and the X can be any amino acids) signals for 4 sequential modifi‐
cations (Figure 3A). Firstly, the cysteine of the CaaX motif is farnesylated by a farnesyltrans‐
ferase (FTase), then the last three amino acids (aaX) are cleaved by a zinc metalloprotease,
ZMPSTE24 (mouse) or FACE-1 (human). Following this cleavage, farnesylated C-termi‐
nal cysteine is methylated by isoprenylcysteine carboxy-methyl transferase (ICMT). Final‐
ly, the last 15 amino acids of the protein are cleaved again by ZMPSTE24, producing
mature lamin A.
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Figure 3. Post-translational processing of pre-lamin A in (A) normal condition and of truncated pre-lamin A (“pre-pro‐
gerin”) in (B) HGPS. The proteolytic cleavage site (RSYLLG motif) lies within the 50 amino acid region that is lost due to
HGPS mutation, and as a result, the ZMPSTE24 endoprotease cannot recognise and perform subsequent upstream
cleavage. Consequently, a truncated lamin A protein (that is, progerin) remains farnesylated, which is believed to have
a dominant negative effect in HGPS.
In HGPS, the first 3 steps of post-translational maturation can be performed (that is, farnesy‐
lation, cleavage, and methylation), while the fourth processing step cannot be completed as
the G608G mutation eliminates the second cleavage site recognised by ZMPSTE24 of pre-
lamin A resulting a permanently farnesylated form of progerin (Figure 3B) [34]. This im‐
properly processed protein in HGPS is thought to underlie the progression of the disease
phenotype [35]. Because progerin, unlike mature lamin A, remains farnesylated, it gains a
high affinity for the nuclear membrane, consequently causing a disruption in the integrity of
the nuclear lamina. Indeed, HGPS patient cells show a number of abnormalities in nuclear
structure and function. Upon indirect immunofluorescence labelling with antibodies direct‐
ed against lamins A/C, fibroblasts from individuals with HGPS were characterised by the
presence of dysmorphic nuclei with altered size and shape, presence of lobules, wrinkles,
herniations of the nuclear envelope, thickening of the nuclear lamina, loss of peripheral het‐
erochromatin, and clustering of nuclear pores [4, 36, 37]. These features worsen with passag‐
es in cell culture and are correlated with an apparent intranuclear accumulation of progerin
(Figure 4) [36, 38]. In addition to permanent farnesylation of the progerin, it has been hy‐
pothesised that the deletion of the phosphorylation site (Ser 625) found in the 50 amino acid-
deleted region may also account for some of the HGPS phenotypes as cell cycle dependent
phosphorylation of lamin A is important for its normal function [4, 39].
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Figure 4. Immunostaining of skin fibroblasts taken from a normal individual (left) and a HGPS patient (right) showing
nuclear blebbing. Lamin A/C is labelled red and lamin B1 in green. Note that the expression of lamin B1 is lost in the
blebbed region. The figure has been adapted from Shimi et al. (2012) [40], with permission from Elsevier.
Numerous studies have addressed the senescent characteristics of HGPS cells, which intri‐
guingly parallel with properties of fibroblasts from aged individuals. Cellular senescence is
a hallmark characteristic of the ageing process, and cell nuclei from old individuals have
similar defects to those of HGPS patient cells, including increased DNA damage [18, 41, 42],
down-regulation of several nuclear proteins, such as the heterochromatin protein HP1 and
the LAP2 group of lamin A-associated proteins [18, 37], and changes in histone modifica‐
tions [18]. Heterochromatin becomes more disorganised with increased ageing in patients
[43], and deregulation of chromatin organisation is a common phenomenon in HGPS, where
progerin is known to alter histone methylation [44, 45]. Interestingly, the cryptic splice site
that is constitutively activated in HGPS is seldom used in “normal” pre-lamin A processing
in healthy aged individuals (Figure 2). To directly demonstrate that the production of pro‐
gerin by sporadic use of the cryptic splice donor site in LMNA exon 11 is responsible for the
observed changes in nuclear architecture in cells from aged individuals, Scaffidi and Mistelli
used a morpholino oligonucleotide to inhibit this cryptic splice site and consequently the
production of progerin and showed that the nuclear defects were reversed [18].
Although the amount of progerin in cells is considerably lower than the amount of lamin A
and lamin C [46], it is obvious that this small amount of progerin is very potent in terms of
causing disease phenotypes in humans and in causing misshaped nuclei in cultured cells.
Supporting the hypothesis that progerin exerts dominant negative effect in HGPS, Goldman
and colleagues introduced progerin into normal cells via transfection and showed that pro‐
gerin is targeted to the nuclear envelope and is entirely responsible for the misshapen nu‐
clei. Same changes were observed when progerin protein was microinjected into cytoplasm
of the normal cells [36]. It was hypothesised that retention of the farnesyl group on progerin
may be the key factor in the development of the HGPS phenotype. Indeed, several different
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research groups showed that the nuclear abnormalities were alleviated or reversed by the
inhibition of farnesylation [47-49]. Briefly, Yang and colleagues used mouse embryonic fi‐
broblasts from a transgenic mouse expressing progerin (LmnaHG/+) and showed that the treat‐
ment with a protein farnesyltransferase inhibitor (FTI) reduced nuclear blebbing to a
baseline level observed in untreated wild-type cells [47]. Capell’s group used transfection
technique to demonstrate that the percentage of blebbed nuclei in HeLa cells that are trans‐
fected with progerin vector, decreased with FTI treatment in a dose-dependent manner [48].
Finally, Glynn and Glover showed a significant improvement in the nuclear morphology of
HGPS cells or cells expressing mutant lamin A following FTI treatment [49].
There are several other de novo dominant LMNA mutations that are found less frequently
and are known to cause atypical HGPS (see review [50]). Clinically, atypical HGPS patients
exhibit additional signs and symptoms of classical HGPS or lack some of phenotypes ob‐
served in classical form. These overlapping and distinct clinical features of atypical HGPS
are well described by Garg and colleagues [51].
4. Animal models
Animal models of HGPS have been a valuable tool in the study of the pathological processes
implicated in the origin of this disease as well as finding a cure. Some of these mouse mod‐
els are designed to express the exact mutation that is observed in human HGPS patients, or
have defect in the lamin A processing. These mouse models are summarised in Table 1.
In 2006, Varga and colleagues generated a transgenic mouse model for HGPS by introduc‐
ing a human bacterial artificial chromosome (BAC) c.1824C>T mutated LMNA gene. These
animals over-expressed human lamin A/C and progerin in all tissues. Although this animal
model did not display any external phenotypes seen in HGPS patients, such as growth retar‐
dation, alopecia, micrognathia and abnormal dentition, it progressively lost vascular smooth
muscle cells in the medial layer of large arteries that closely resembled the most deadly as‐
pect of the HGPS patients. Surprisingly, these animals showed no differences in their life ex‐
pectancy compared to their wild-type littermates [52].
The Zmpste24-/- model was first developed by Leung and co-workers [53]. This model is a
complete knock-out model, in which animals do not have any ZMPSTE24 enzyme. Disrup‐
tion of the gene encoding ZMPSTE24 in mice causes defective lamin A processing, which
results in the accumulation of farnesylated pre-lamin A at the nuclear envelope [54, 55].
Since these ZMPSTE24-deficient mice have shown to have many features that resemble
HGPS and other laminopathies (diseases that are caused by mutations in the nuclear lami‐
na), this model has served as a crucial tool to explore the mechanisms underlying these dis‐
eases and to design therapies for the treatment [55, 56]. In addition to being a model for
HGPS, Zmpste24-/- mice also showed numerous characteristics of mandibuloacral dysplasia
(MAD) [54], which promoted researchers to search for ZMPSTE24 mutations in MAD pa‐
tients [57]. Furthermore, loss of ZMPSTE24 in humans has been shown to cause restrictive
dermopathy, a lethal perinatal progeroid syndrome characterised by tight and rigid skin
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with erosions, loss of fat and prominent superficial vasculature, thin hair, micrognathia,
joint contractures, and thin dysplastic clavicles [58]. The Zmpste24-/- mice look normal at
birth, but develop skeletal abnormalities with spontaneous bone fractures. Furthermore,
they show progressive hair loss, abnormal teething, muscle weakness, which ultimately lead
to premature death at the age of 20-30 weeks [54, 55].
As an additional proof of the toxic effects of pre-lamin A accumulation, Fong and others
compared the phenotypes of Zmpste24-/- mice and littermate Zmpste24-/- mice bearing one
Lmna knock-out allele (Zmpste24-/-Lmna+/-) [59]. In this study, the authors showed that double
knock-out mice carrying the Zmpste24-/-Lmna+/- genotype, expressing half the pre-lamin A of
Zmpste24-/-Lmna+/+ mice were completely protected from all disease phenotypes, including
reduced growth rate, muscle strength and impaired bone and soft tissue development, and
shortened lifespan. Furthermore, the frequency of misshapen nuclei in Zmpste24-/-Lmna+/- fi‐
broblasts was significantly lower than fibroblasts from Zmpste24-/-Lmna+/+ mice. The results
from this study not only suggest that the accumulation of the farnesylated pre-lamin A is
toxic, but also show that lowering the level of pre-lamin A have a beneficial effect on disease
phenotypes in mice and on nuclear shape in cultured cells [59].
The LmnaHG/+ model is a progerin knock-in mouse model, in which one of the LMNA alleles
only expresses progerin, while the other expresses lamin A/C. These animals show several
HGPS-related phenotypes, including bone alterations, reduction in subcutaneous fat and
premature death at around 28 weeks of age [47, 60]. Although LmnaHG/+ mice clearly show
many of the early symptoms of HGPS, they do not display any signs of atherosclerosis in the
intima or media of the aorta. This was surprising as most of HGPS patients die from cardio‐
vascular complications and authors speculated that absence of these cardiovascular-related
phenotypes in LmnaHG/+ mice is simply because these mice do not live long enough to devel‐
op these deficits [60]. In the homozygous LmnaHG/HG animals, both LMNA alleles express
progerin and therefore, lamin A/C is not produced. These animals exhibit severe growth re‐
tardation with complete absence of adipose tissue and numerous spontaneous bone frac‐
tures. They die at 3-4 weeks of age with poorly mineralised bones, micrognathia,
craniofacial abnormalities [60].
In all of the mouse models described above, both pre-lamin A and progerin are farnesylat‐
ed. Since the disease phenotypes in LmnaHG/+ mice were alleviated with a FTI, it was logi‐
cal to suppose that the protein prenylation is important for disease pathogenesis [60-62].
To further elucidate this subject, Yang et al. created a knock-in mice expressing non-farne‐
sylated progerin (LmnanHG/+), in which progerin’s C-terminal –CSIM motif was changed to
–SSIM. This single amino acid substitution eliminated protein prenylation and two follow‐
ing processing steps (cleavage of the last 3 amino acids and methylation, Figure 3) [63].
Yang and colleagues expected that LmnanHG/+ mice would be free of disease, but surprising‐
ly these animals developed all of the same disease phenotypes found in LmnaHG/+ mice and
invariably  succumbed to  the  disease  [63].  Persistence  of  disease  phenotype in  LmnanHG/+
mice, though milder than LmnaHG/+ mice, raised doubts about the primacy of the protein pre‐
nylation in disease pathogenesis suggesting that features of progerin other than the accu‐
mulation of farnesylated progerin may underlie the severity of the disease [63]. In order to
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investigate the toxicity of the non-farnesylated progerin produced by the LmnanHG  allele,
Yang et al. generated another non-fanesylated progerin allele (LmnacsmHG), in which the pro‐
gerin’s C-terminal ends with the –CSM compared to the –SSIM ending in LmnanHG  allele
[64]. CSM progerin cannot be prenylated, but it retains a C-terminal cysteine similar to the
CSIM progerin that accumulates in FTI-treated LmnaHG/+ mice. Astonishingly, mice contain‐
ing  the  LmnacsmHG  allele  were  free  of  HGPS-like  disease  phenotypes.  Even the  homozy‐
gous mice (LmnacsmHG/csmHG), which produce exclusively progerin and no lamin A/C, were
absent of all the characteristics of HGPS [64]. Furthermore, nuclear abnormalities were al‐
so milder in both types of mice. This study demonstrated that the toxicity of non-farnesy‐
lated progerin  depends  on the  mutation used to  abolish  protein  farnesylation [64].  The
absence of HGPS-like phenotypes in mice expressing LmnacsmHG allele is consistent in mice
expressing farnesylated and non-farnesylated forms of pre-lamin A. While expression of far‐
nesylated pre-lamin A in Zmpste24-/- mice results in a severe HGPS-like symptoms [54, 59,
65, 66], mice expressing non-farnesylated pre-lamin A (LmnanPLAO/nPLAO) exhibited no HGPS-
like phenotypes [67].
Although all differentiated cells express lamin A [22], there is still no clear explanation as to
why the HGPS-related symptoms are limited to particular tissues and organs. Due to this
segmental nature of HGPS with clinical features only present in restricted tissues, develop‐
ing an ideal representative mouse model for HGPS has been a challenge. However, by using
tissue-specific promoters, researchers have succeeded in designing transgenic mouse mod‐
els expressing progerin in specific tissues. Unlike general knock-out or knock-in mouse
models, transgenic mouse models using tissue-specific promoters provide a wealth of infor‐
mation about the function of specific genes, the LMNA, in case of HGPS. For example, Wang
and others created a transgenic mouse line that expresses progerin in the epidermis by using
the keratin 14 promoter [68]. Although keratinocytes of these mice showed abnormalities in
nuclear morphology, their hair growth and wound healing were normal [68]. Although the
advantages in using tissue-specific promoters to directly control the expression of target
genes in specified tissues in transgenic animals have been acknowledged, the limitations of
this system had become clear. This constitutive system had no control over the timing of the
target gene expression, which depend entirely on the properties of the promoters used. The
promoters in this setting is constitutively active, many starting early in the embryonic stage.
In order to overcome this drawback, numerous researchers have invested time and effort in
establishing conditional or inducible transgenic modelling system, one of which is regulated
by tetracycline. The tetracycline-controlled transcriptional regulation system (tet-on/off) is a
binary transgenic system that enables spatial and temporal regulation of gene expression
[69]. By adding/removing doxycycline (a tetracycline derivative) to/from the system, it is
possible to switch on/off the expression of the target gene in in vivo, which in turn is under
the control of the tissue specific promoter. Using this system, Eriksson’s group has generat‐
ed a number of transgenic mouse models that express the HGPS mutation in isolated organ
systems [70, 71], which served as a useful tool to study mechanism of disease progress.
Briefly, transgenic mice carrying a human minigene of lamin A with the most common
HGPS mutation, c.1824C>T; p.G608G, under the control of the tetracycline-regulated (tet-off)
keratin 5 promoter (K5tTA) expressed the mutation in the skin, ameloblasts layer of the
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teeth, salivary glands, oesophagus, stomach, tongue, nose cavity and trachea [70]. These ani‐
mals showed growth retardation, hair thinning, tooth fractures and premature death, all of
which are similar clinical features observed in HGPS patients [70]. In order to study skeletal
abnormalities of HGPS, the osterix (Sp7-tTA) promoter was used to create a bone-specific
expression model of the HGPS mutation with expression of the HGPS mutation during os‐
teoblast development (tetop-LAG608G; Sp7-tTA mice). These mice showed growth retardation,
gait imbalance and abnormalities in bone structure [71]. Recently, Osorio and colleagues
have designed another mouse model expressing the HGPS mutation [72]. In this knock-in
mouse model, the wild-type mouse LMNA gene was replaced with a mutant allele that car‐
ried the c.1827C>T; p.G609G mutation, which is equivalent to the HGPS c.1824C>T; p.G608G
mutation in the human LMNA gene (LmnaG609G/G609G). These mice accumulate progerin and
exhibit key clinical features of HGPS, such as shortened life span and bone and cardiovascu‐
lar abnormalities [72].
Mouse Model Description References
BAC transgenic G608G Over expression of human lamin A/C and progerin [51]
Zmpste24-/- Knockout of the gene encoding Zmpste24 [53, 54]
Zmpste24-/- Lmna+/-
Intercross between Zmpste24-/- mice and Lmna+/- mice
No expression of Zmpste24 with only one allele expressing
lamin A/C
[58]
LmnaHG/+ One allele expresses progerin, while the other expresses laminA/C [46, 59]
LmnanHG/+ One allele expresses non-farnesylated progerin, while the otherexpresses lamin A/C [62]
LmnacsmHG/csmHG
Both alleles express non-fanesylated progerin allele (LmnacsmHG),
in which the progerin’s C-terminal ends with the –CSM
compared to the –SSIM ending in LmnanHG allele
[63]
K14 promoter – FLAG - progerin Tissue specific over expression of progerin with FLAG tag [67]
tetop-LAG608G; K5-tTA Tissue specific over expression of human lamin A and progerinby using a Keratin 5 promoter [69]
tetop-LAG608G; Sp7-tTA Bone specific over expression of human lamin A and progerin byusing a osterix promoter [70]
LmnaG609G/G609G
Lmna gene replaced with a mutant allele that carries the c.
1827C>T; p.G609G mutation, which is equivalent to the HGPS c.
1824C>T; p.G608G mutation in the human LMNA gene
[71]
Table 1. A summary table of the most relevant mouse models for HGPS.
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5. Treatments
Although the cause of HGPS has been discovered nearly 10 years ago, HGPS remains in‐
curable, with no therapy other than symptomatic treatment. Nevertheless, not long after the
discovery of a mutation in LMNA gene as the cause of HGPS, a number of potential thera‐
peutic strategies have emerged. A great deal of evidence suggests that the accumulation of
progerin may be the key to the pathogenesis of HGPS [18, 20, 30, 31, 36, 72]. As progerin is
permanently farnesylated, researchers initially turned to farnesyltransferase inhibitors
(FTIs) in the search for a pathogenic treatment. FTIs were initially developed for the treat‐
ment of cancer [73]. The theory to this invention was simple: to abolish the farnesyl lipid
from mutationally activated Ras proteins, thus mislocalising these signalling proteins away
from the plasma membrane, where they stimulate uncontrolled cell division. Analogous
concept was applied to HGPS: to mislocalise farnesylated progerin away from the nuclear
envelope, with the hope that the mislocalisation would reduce the ability of the molecule to
cause disease. However, potential shortcomings to the FTI treatment were recognised from
the start. For example, these drugs would be expected to interfere with the farnesylation of
lamin B1 and B2, possibly causing more damage to the nuclear lamina. Moreover, these mol‐
ecules would be expected to disturb farnesylation of other cellular proteins, possibly loading
a second insult on already compromised cells. Finally, there was a concern that pre-lamin A
might be geranylgeranylated in the presence of FTI, in which case would forbid the overall
strategy. Indeed, negative effects of FTI treatment were reported both in vitro and in vivo by
Verstraeten and colleagues. They showed that FTI treatment caused defects in centrosome
separation leading to donut-shaped nuclei [74]. However, despite these concerns, investiga‐
tors cautiously raised their hopes about the possibility of testing FTIs in HGPS.
In 2004, it was first hypothesised that farnesylated progerin might be a key player in the
pathogenesis of HGPS [59]. Within a year, Yang et al. generated a mice carrying a “progerin-
only” Lmna allele (LmnaHG/+) and showed that the number of LmnaHG/+ fibroblasts with mis‐
shapen nuclei was significantly decreased following the treatment of a FTI [47]. Shortly
thereafter, several groups reported similar observations and demonstrated the possibility of
farnesyltransferase inhibition as a therapeutic strategy for HGPS [48, 49, 75]. The finding
that FTIs improve nuclear abnormalities led to testing the efficacy of FTIs in mouse models
of HGPS. Fong et al. showed that administration of FTI restored disease phenotypes in
Zmpste24 deficient (Zmpste24-/-) mice [76], and Yang et al. found that FTI significantly allevi‐
ated HGPS-related disease phenotypes (e.g. rib fractures, body weight curves, reduced bone
density) and increased the survival of mice with a HGPS mutation (LmnaHG/+) [60, 62]. Fur‐
thermore, Capell and colleagues demonstrated that treatment with FTI to HGPS mouse
(BAC transgenic G608G; [52]) significantly prevented both the onset and late progression of
cardiovascular disease, which is one of the most prevalent cause of death in HGPS patients
[77]. However, some of enthusiasm about FTI treatment was dampened by unexpected
emergence of HGPS-related disease phenotypes in mice expressing non-farnesylated pro‐
gerin (LmnanHG/+) [63]. In order to further elucidate the fact that protein farnesylation is rele‐
vant to the pathogenesis and treatment of disease, Yang and others compared the effects of
an FTI on disease phenotypes in both LmnaHG/+ and LmnanHG/+ mice [61]. In this study, au‐
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thors showed that the FTI reduced disease phenotypes only in LmnaHG/+ mice, and had no
effect in LmnanHG/+ mice, which supported the idea that the beneficial effects of FTI in
LmnaHG/+ mice are due to the inhibition of progerin farnesylation [61].
The encouraging results from both cell and animal studies led to the initiation of the clinical
trial with FTI for HGPS patients. In 2007, 28 patients with classical HGPS were enrolled for
the first clinical trial, in which children were treated with Lonafarnib (an FTI) for 2 years.
Although the trial ended in December 2009, no report has been published on how effective
the drug was in treating HGPS. While this first trial was in progress, the statins and amino‐
bisphosphonates gained attention as potential therapies for the treatment of HGPS. Varela
and others reported that combined treatment with statins and aminobisphosphonates effec‐
tively inhibit the farnesylation and gernaylgeranylation (an alternative prenylation) of pro‐
gerin and pre-lamin A, which was accompanied by an alleviation in the disease phenotype
of the Zmpste24-/- knockout mice [78]. Statins and aminobisphosphonates, both inhibit pro‐
tein prenylation at different points than FTIs in the isoprenoids and cholesterol biosynthetic
pathway, and are already in clinical use (Figure 5). Statins are renowned inhibitors of cho‐
lesterol synthetic pathway and are widely used in the clinic to lower cholesterol level and
prescribed for cholesterol associated diseases, such as atherosclerosis. Statins inhibit the pro‐
duction of isoprenoid precursors involved in protein modification, thereby inhibiting lamin
A maturation [79-81]. The aminobisphosphonates are currently used to treat osteoporosis. It
inhibits farnesylpyrophosphate synthase, thus reducing the production of both geranyl-ger‐
anyl and farnesyl group [82, 83]. In addition to results from Varela et al. [78], Wang and col‐
leagues also showed that treatment of transgenic mice that express progerin in epidermis
with a FTI or a combination of a statin plus an aminobisphosphonate significantly improved
nuclear morphological abnormalities in intact tissue [84]. Based on these hopeful animal
studies, the Triple Drug Trial to test the therapeutic effect of a combination of a statin (Pra‐
vastatin), a biosphosphonate (Zoledronic Acid), and a FTI (Lonafarnib) was initiated in Au‐
gust 2009, including 45 HGPS patients [5]. This trial was planned to last for 2 years, but
announcement about its outcome is yet to be made.
Besides interfering the post-translational processing of mutated pre-lamin A, another major
path for HGPS treatment is to reduce the expression of progerin in cells and tissue [37, 72,
85, 86]. This was first shown by Scaffidi and Misteli [37]. They used antisense morpholino
oligonucleotides specifically directed against the aberrant exon 11 and exon 12 junction con‐
tained in mutated pre-mRNAs to target the splicing defect observed in HGPS, and conse‐
quently decrease the production of progerin. Authors showed that once splicing defect is
corrected and the level of progerin is decreased, morphological abnormalities of HGPS fi‐
broblasts were ameliorated [37]. More recently, Osorio et al. designed a 25-nucleotide mor‐
pholino that bound to the exon 10-lamin A splice donor site, and showed that its
administration reduced the percentage of cells with nuclear abnormalities to wild-type lev‐
els in a dose-dependent manner [72]. It remains to be seen, however, whether these oligonu‐
cleotides can be effectively and safely administered to patients. Another approach to reduce
progerin expression at mRNA level is to use a short hairpin RNA (shRNA). Huang and col‐
leagues showed that the reduced expression of mutated LMNA mRNA level was associated
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with amelioration of abnormal nuclear morphology [86]. However, the efficacy of shRNA in
whole organism is yet to be confirmed.
Figure 5. Isoprenoids and cholesterol biosynthetic pathway and its inhibitors for the treatment possibilities of HGPS.
PP stands for pyrophosphate.
More recently, rapamycin has been gaining much attention as a new candidate for the treat‐
ment of HGPS. Rapamycin (also known as Sirolimus) is an FDA-approved drug that has
been used for a long time in transplant patients as an anti-rejection drug. In addition to its
historical use as an immunosuppressant, pre-clinical studies demonstrated life-span extend‐
ing effect of rapamycin or rapamycin derivatives in mice [87, 88]. The effect of rapamycin is
due to the inhibition of mammalian target of rapamycin (mTOR) pathway by rapamycin
and is at least partly dependant on autophagy [89, 90]. Cao and colleagues have recently
demonstrated that HGPS cells treated with rapamycin showed enhanced progerin degrada‐
tion, slowed senescence, and reduced nuclear blebbing compared to untreated cells [91, 92].
Furthermore, similar results were reported by Cenni and others [93]. Since rapamycin is al‐
ready an approved drug, its effect should be further examined in mouse models of HGPS
and considered as a potential therapy for HGPS patients.
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6. Conclusion
Since the discovery of the genetic basis for HGPS almost a decade ago, there has been prog‐
ress in understanding the mechanism(s) of this premature ageing syndrome and its possible
implications for physiological ageing. Results from numerous studies have uniformly sug‐
gested that the accumulation of an abnormally processed lamin A protein, progerin, medi‐
ates dominant-negative effects in cells from HGPS patients. Notably, over the last few years,
many achievements in basic research have driven the development of potential therapies
which have resulted in several clinical trials for patients with HGPS. It was inevitable to
have hopes that these compounds targeting the isoprenoids and cholesterol biosynthetic
pathway would alleviate the clinical course of HGPS. Nevertheless, drugs that are currently
in clinical trials do not have the ability to target the cryptic splice site; therefore, additional
approaches may still need to be considered.
In summary, by better understanding the mechanisms of HGPS, it may be possible to mini‐
mise the pathological process observed in HGPS, and to develop potential treatments for
age-related diseases.
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